Alkem reports posts Q1 FY26 net profit 22% higher at 664.3 Cr
Alkem’s domestic business grew 9.7 per cent versus the Indian pharmaceutical market growth of 8.5 per cent
Alkem’s domestic business grew 9.7 per cent versus the Indian pharmaceutical market growth of 8.5 per cent
The collaboration will combine Firstsource’s AI-first approach with Guidehealth’s expertise in value-based care innovation
The company’s virgin PET chips plant in Egypt, commissioned in Q4 FY25, achieved 74.8 per cent capacity utilization in its first full quarter. In India, the Panipat facility operated at 96.6 per cent utilization
The CRDMO segment contributed Rs. 452.7 crore, recording a robust 70.5 per cent YoY increase
During the quarter, construction began on a US$ 10 million bioconjugation cGMP suite at NJ Bio’s Princeton site
The therapy delivers the full-length ABCA4 protein and has the potential to benefit all patients with ABCA4 mutations
EBITDA stood at Rs. 100.1 crore with a margin of 16.1 per cent
The company reported revenue from operations at Rs. 6,573.7 crore, up 6 per cent YoY
AINU is set to accelerate its expansion footprint, enhance operational capabilities
Subscribe To Our Newsletter & Stay Updated